头孢他洛滨-他唑巴坦和头孢他啶-阿维巴坦对β-内酰胺类耐药铜绿假单胞菌分离株的活性。
Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates.
机构信息
Department of Pathology and Laboratory Medicine, University of California, Los Angeles, California, USA
Department of Pathology and Laboratory Medicine, University of California, Los Angeles, California, USA.
出版信息
Antimicrob Agents Chemother. 2017 Nov 22;61(12). doi: 10.1128/AAC.01858-17. Print 2017 Dec.
Abstract
Ceftolozane-tazobactam (C/T) and ceftazidime-avibactam (CZA) MICs were evaluated for a collection of 309 beta-lactam-resistant isolates of recovered from three institutions in the area of Los Angeles, CA. Overall, 12.0% of isolates were susceptible to imipenem, 15.9% were susceptible to meropenem, 20.7% were susceptible to piperacillin-tazobactam, 24.6% were susceptible to ceftazidime, 25.9% were susceptible to cefepime, 72.5% were susceptible to C/T, and 61.8% were susceptible to CZA. Among C/T-resistant isolates, 9.1% were CZA susceptible, whereas 36.4% of CZA-resistant isolates were susceptible to C/T.
摘要
对从加利福尼亚州洛杉矶地区的三个机构中分离出的 309 株β-内酰胺耐药株进行了头孢洛扎他唑巴坦（C/T）和头孢他啶-阿维巴坦（CZA）的 MIC 评估。总体而言，12.0%的分离株对亚胺培南敏感，15.9%的分离株对美罗培南敏感，20.7%的分离株对哌拉西林他唑巴坦敏感，24.6%的分离株对头孢他啶敏感，25.9%的分离株对头孢吡肟敏感，72.5%的分离株对 C/T 敏感，61.8%的分离株对 CZA 敏感。在 C/T 耐药株中，9.1%的分离株对 CZA 敏感，而 36.4%的 CZA 耐药株对 C/T 敏感。
相似文献
1
Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates.
Antimicrob Agents Chemother. 2017 Nov 22;61(12). doi: 10.1128/AAC.01858-17. Print 2017 Dec.
2
Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates.
Antimicrob Agents Chemother. 2016 Apr 22;60(5):3227-31. doi: 10.1128/AAC.02969-15. Print 2016 May.
3
Comparison of antimicrobial activity between ceftolozane-tazobactam and ceftazidime-avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.
Int J Infect Dis. 2017 Sep;62:39-43. doi: 10.1016/j.ijid.2017.06.007. Epub 2017 Jun 10.
4
Comparison of Ceftolozane-Tazobactam to Traditional Beta-Lactams and Ceftolozane-Tazobactam as an Alternative to Combination Antimicrobial Therapy for Pseudomonas aeruginosa.
Antimicrob Agents Chemother. 2017 Nov 22;61(12). doi: 10.1128/AAC.01350-17. Print 2017 Dec.
5
In vitro activity of ceftolozane-tazobactam and ceftazidime-avibactam against clinical isolates of meropenem-non-susceptible Pseudomonas aeruginosa: A two-centre study.
J Glob Antimicrob Resist. 2020 Mar;20:334-338. doi: 10.1016/j.jgar.2019.09.016. Epub 2019 Sep 27.
6
Assessment of the Activities of Ceftolozane/Tazobactam and Ceftazidime/Avibactam in a Collection of Beta-Lactam-Resistant Enterobacteriaceae and Clinical Isolates at Montpellier University Hospital, France.
Microb Drug Resist. 2019 Nov;25(9):1325-1329. doi: 10.1089/mdr.2018.0439. Epub 2019 Jun 21.
7
In Vitro Activity of Ceftazidime-Avibactam against Contemporary Pseudomonas aeruginosa Isolates from U.S. Medical Centers by Census Region, 2014.
Antimicrob Agents Chemother. 2016 Mar 25;60(4):2537-41. doi: 10.1128/AAC.03056-15. Print 2016 Apr.
8
Integrated Genome-Wide Analysis of an Isogenic Pair of Clinical Isolates with Differential Antimicrobial Resistance to Ceftolozane/Tazobactam, Ceftazidime/Avibactam, and Piperacillin/Tazobactam.
Int J Mol Sci. 2020 Feb 4;21(3):1026. doi: 10.3390/ijms21031026.
9
The ERACE-PA Global Surveillance Program: Ceftolozane/tazobactam and Ceftazidime/avibactam in vitro Activity against a Global Collection of Carbapenem-resistant Pseudomonas aeruginosa.
Eur J Clin Microbiol Infect Dis. 2021 Dec;40(12):2533-2541. doi: 10.1007/s10096-021-04308-0. Epub 2021 Jul 22.
10
Multicenter Evaluation of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Inhibitory Activity against Meropenem-Nonsusceptible Pseudomonas aeruginosa from Blood, Respiratory Tract, and Wounds.
Antimicrob Agents Chemother. 2017 Sep 22;61(10). doi: 10.1128/AAC.00875-17. Print 2017 Oct.
引用本文的文献
1
Multi-Drug Resistant Gram-Negative Sepsis in Neonates: The Special Role of Ceftazidime/Avibactam and Ceftolozane/Tazobactam.
Medicines (Basel). 2025 Jun 26;12(3):17. doi: 10.3390/medicines12030017.
2
Assessment of in vitro antimicrobial activities of ceftolozane/tazobactam and ceftazidime/avibactam against carbapenem-resistant Pseudomonas aeruginosa clinical isolates.
BMC Infect Dis. 2025 Apr 28;25(1):622. doi: 10.1186/s12879-025-10891-w.
3
Global trends of ceftazidime-avibactam resistance in gram-negative bacteria: systematic review and meta-analysis.
Antimicrob Resist Infect Control. 2025 Feb 11;14(1):10. doi: 10.1186/s13756-025-01518-5.
4
Guidelines for Antibiotics Prescription in Critically Ill Patients.
Indian J Crit Care Med. 2024 Aug;28(Suppl 2):S104-S216. doi: 10.5005/jp-journals-10071-24677. Epub 2024 Aug 10.
5
Antimicrobial susceptibility profile of ceftolozane/tazobactam, ceftazidime/avibactam and cefiderocol against carbapenem-resistant Pseudomonas aeruginosa clinical isolates from Türkiye.
Eur J Clin Microbiol Infect Dis. 2024 Sep;43(9):1787-1794. doi: 10.1007/s10096-024-04896-7. Epub 2024 Jul 12.
6
Antimicrobial and Diagnostic Stewardship of the Novel β-Lactam/β-Lactamase Inhibitors for Infections Due to Carbapenem-Resistant Enterobacterales Species and .
Antibiotics (Basel). 2024 Mar 21;13(3):285. doi: 10.3390/antibiotics13030285.
7
Approaches to Testing Novel β-Lactam and β-Lactam Combination Agents in the Clinical Laboratory.
Antibiotics (Basel). 2023 Dec 5;12(12):1700. doi: 10.3390/antibiotics12121700.
8
Novel Beta Lactam Antibiotics for the Treatment of Multidrug-Resistant Gram-Negative Infections in Children: A Narrative Review.
Microorganisms. 2023 Jul 13;11(7):1798. doi: 10.3390/microorganisms11071798.
9
Ceftolozane-Tazobactam Versus Ceftazidime-Avibactam for the Treatment of Infections Caused by Multidrug-Resistant Pseudomonas aeruginosa: a Multicenter Cohort Study.
Antimicrob Agents Chemother. 2023 Aug 17;67(8):e0040523. doi: 10.1128/aac.00405-23. Epub 2023 Jul 5.
10
Activity of newest generation β-lactam/β-lactamase inhibitor combination therapies against multidrug resistant Pseudomonas aeruginosa.
Sci Rep. 2022 Oct 7;12(1):16814. doi: 10.1038/s41598-022-21101-x.
本文引用的文献
1
Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: Clinical Effectiveness and Evolution of Resistance.
Clin Infect Dis. 2017 Jul 1;65(1):110-120. doi: 10.1093/cid/cix182.
2
Multicenter Evaluation of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Inhibitory Activity against Meropenem-Nonsusceptible Pseudomonas aeruginosa from Blood, Respiratory Tract, and Wounds.
Antimicrob Agents Chemother. 2017 Sep 22;61(10). doi: 10.1128/AAC.00875-17. Print 2017 Oct.
3
Activity of ceftolozane/tazobactam against surveillance and 'problem' Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British Isles.
J Antimicrob Chemother. 2017 Aug 1;72(8):2278-2289. doi: 10.1093/jac/dkx136.
4
Ceftolozane-Tazobactam Activity against Pseudomonas aeruginosa Clinical Isolates from U.S. Hospitals: Report from the PACTS Antimicrobial Surveillance Program, 2012 to 2015.
Antimicrob Agents Chemother. 2017 Jun 27;61(7). doi: 10.1128/AAC.00465-17. Print 2017 Jul.
5
Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa.
Clin Infect Dis. 2017 Jul 1;65(1):158-161. doi: 10.1093/cid/cix014.
6
Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15).
J Antimicrob Chemother. 2017 May 1;72(5):1386-1395. doi: 10.1093/jac/dkx009.
7
Susceptibility of Ceftolozane-Tazobactam and Ceftazidime-Avibactam Against a Collection of β-Lactam-Resistant Gram-Negative Bacteria.
Ann Lab Med. 2017 Mar;37(2):174-176. doi: 10.3343/alm.2017.37.2.174.
8
Antimicrobial Activities of Ceftazidime-Avibactam and Comparator Agents against Gram-Negative Organisms Isolated from Patients with Urinary Tract Infections in U.S. Medical Centers, 2012 to 2014.
Antimicrob Agents Chemother. 2016 Jun 20;60(7):4355-60. doi: 10.1128/AAC.00405-16. Print 2016 Jul.
9
Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations.
Clin Infect Dis. 2016 Jul 15;63(2):234-41. doi: 10.1093/cid/ciw243. Epub 2016 Apr 20.
10
Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates.
Antimicrob Agents Chemother. 2016 Apr 22;60(5):3227-31. doi: 10.1128/AAC.02969-15. Print 2016 May.
Zotero 插件